Global Blood Therapeutics, Inc. (NASDAQ:GBT – Get Rating) – Research analysts at Cantor Fitzgerald issued their FY2023 earnings per share estimates for Global Blood Therapeutics in a report issued on Monday, June 6th. Cantor Fitzgerald analyst L. Watsek expects that the company will earn ($3.03) per share for the year. Cantor Fitzgerald has a “Buy” rating and a $75.00 price target on the stock.
Global Blood Therapeutics (NASDAQ:GBT – Get Rating) last issued its quarterly earnings data on Wednesday, May 4th. The company reported ($1.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.29) by $0.03. Global Blood Therapeutics had a negative net margin of 146.82% and a negative return on equity of 129.74%. The business had revenue of $55.20 million during the quarter, compared to the consensus estimate of $56.13 million. During the same period in the prior year, the firm posted ($1.21) EPS. The firm’s quarterly revenue was up 41.5% compared to the same quarter last year.
Shares of GBT stock opened at $24.50 on Wednesday. Global Blood Therapeutics has a 52-week low of $22.67 and a 52-week high of $41.73. The company has a quick ratio of 7.74, a current ratio of 8.52 and a debt-to-equity ratio of 4.34. The company has a 50-day simple moving average of $30.27 and a two-hundred day simple moving average of $29.90.
Several institutional investors have recently bought and sold shares of the company. Huntington National Bank raised its position in Global Blood Therapeutics by 90,600.0% in the 4th quarter. Huntington National Bank now owns 907 shares of the company’s stock worth $27,000 after purchasing an additional 906 shares during the period. SkyView Investment Advisors LLC raised its position in Global Blood Therapeutics by 587.2% in the 1st quarter. SkyView Investment Advisors LLC now owns 804 shares of the company’s stock worth $28,000 after purchasing an additional 687 shares during the period. US Bancorp DE raised its position in Global Blood Therapeutics by 52.7% in the 3rd quarter. US Bancorp DE now owns 1,385 shares of the company’s stock worth $36,000 after purchasing an additional 478 shares during the period. Nisa Investment Advisors LLC raised its position in Global Blood Therapeutics by 75.6% in the 1st quarter. Nisa Investment Advisors LLC now owns 1,510 shares of the company’s stock worth $52,000 after purchasing an additional 650 shares during the period. Finally, Advisor Group Holdings Inc. raised its position in Global Blood Therapeutics by 31.8% in the 4th quarter. Advisor Group Holdings Inc. now owns 1,865 shares of the company’s stock worth $55,000 after purchasing an additional 450 shares during the period.
Global Blood Therapeutics Company Profile (Get Rating)
Global Blood Therapeutics, Inc, a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD.
- Get a free copy of the StockNews.com research report on Global Blood Therapeutics (GBT)
- Heavy Buying Points to Upside for These 3 Stocks
- 3 Intriguing Stocks With Sub-10 P/E Ratios
- Snap Inc: Revised Guidance & Steeping Losses
- Time to Buy Take-Two Interactive Stock
- 3 Software Plays Showing Signs of Recovery
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.